Investornewsbreaks Predictive Oncology Inc. (NASDAQ: POAI) Expands Its AI/ML Driven Platform To Include Novel Oncology Biomarker Discovery

(MENAFN- Investor Brand Network) Predictive Oncology (NASDAQ: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities to accelerate oncology drug discovery and enable drug development, is expanding its AI/ML driven drug discovery platform. According to the company, the expansion will include novel oncology biomarker discovery to be used to predict patient outcomes and drug response in oncology. This expansion marks the company's entry into the biomarker discovery market, which is estimated by third party research to be $51.5 billion in 2024.“We have already demonstrated the capabilities of our active machine learning platform to selectively utilize our diverse patient samples preserved in our biobank to predict responses to drugs with a very high degree of accuracy,” stated Arlette H. Uihlein, MD, SVP, Translational Medicine and Drug Discovery and Medical Director at Predictive Oncology.“We are now taking this one step further by applying state-of-the-art deep learning approaches for biomarker discovery related to both patient overall survival (“OS”) and drug response, which can be done with existing resources. Our platform enables us to apply deep learning to the correct patient cohorts and accelerate the initial stages of biomarker discovery.”

To view the full press release, visit

About Predictive Oncology Inc.

Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence (“AI”) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company's scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent
in-vitro testing. With the company's vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry's broadest AI-based, drug-discovery solutions, further complemented by its wholly owned Clinical Laboratory Improvement Amendments (“CLIA”) lab and GMP facilities. For more information about the company, please visit
.

NOTE TO INVESTORS:
The latest news and updates relating to POAI are available in the company's newsroom at

About InvestorWire

InvestorWire
(“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:
/Disclaimer

InvestorWire
Los Angeles, CA

310.299.1717 Office
...

InvestorWire is powered by
IBN

MENAFN25072024000224011066ID1108483136